Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

What are we looking for?

Reasonably valued U.S. health-care stocks poised for earnings growth.

Over the past year, this sector has underperformed the broader market by a fairly wide margin: Health-care stocks have risen approximately 11 per cent compared with more than 25 per cent for some sectors such as technology, industrials and consumer goods. After a strong start following Donald Trump's surprise election last fall, health-care stocks have languished under uncertainty over attempts to reform the Affordable Care Act (Obamacare) and possible regulation of drug prices. In the context of an overheated U.S. market, health-care stocks now represent an interesting opportunity.

The screen

We will be using Recognia Strategy Builder to search for U.S. health-care stocks with reasonable valuations and set for continued earnings growth.

We begin by setting a minimum market-capitalization threshold of $15-billion (U.S.) to focus on larger, more stable and established companies in the sector. Next, we will look for companies that are currently reasonably valued based on their forward price-to-earnings ratios. We will select only stocks with P/E ratios below 25. We will also look for stocks with projected earnings-per-share growth rates this year of at least 10 per cent.

Finally, in order to select stocks that are preferred by analysts, we will filter on companies with analysts' consensus ratings of either buy or strong buy.

More about Recognia

Recognia is a global leader in automated quantitative analysis and engagement solutions for retail online brokers and institutions. Recognia's product suite provides actionable trading ideas based on technical and fundamental research covering stocks, ETFs, indexes, forex, options and commodities.

What did we find?

Topping our list is pharmaceutical provider Allergan PLC, maker of generic and branded drugs such as Botox. Allergan stock is down more than 30 per cent from July when it announced second-quarter results showing a higher than expected loss in the quarter. Despite this setback, a consensus of analysts covering the stock still rate it a buy. The company has a projected EPS growth rate of 20.3 per cent this year.

Celgene is another pharmaceutical giant whose share price has suffered recently. Celgene released third-quarter results on Oct. 26 in which the company lowered its guidance on revenue for the coming year. This resulted in a one-day decline of 16 per cent for the stock. This drop erased one year of gains and has left Celgene with a very attractive forward P/E ratio of 13.9.

The largest company on our list is Abbott Labs, a pharmaceutical giant with a large portfolio of branded drugs. In spite of its size, Abbott is projected to grow earnings by 13.4 per cent this year and has a consensus analyst rating of buy.

The investment ideas presented here are for information only. They do not constitute advice or a recommendation by Recognia Inc. in respect of the investment in financial instruments. Investors should conduct further research before investing.

Peter Ashton is vice-president of retail and self-directed investing at Recognia Inc.

Health-care stocks offering good value

RankCompanySymbolAnalyst Consensus RatingMarket Cap. ($Bil U.S.)Fwd P/E RatioEPS Growth*Dividend Yield
1Allergan PLCAGN-NBuy$57.50 10.820.30%1.60%
2Shire PLCSHPG-QBuy$43.80 9.513.40%0.60%
3Celgene Corp.CELG-QBuy$80.60 13.923.50%0.00%
4Eli Lilly and Co.LLY-NBuy$91.70 20.219.70%2.50%
5Alexion Pharmaceuticals Inc.ALXN-QBuy$26.20 20.722.40%0.00%
6Thermo Fisher Scientific Inc.TMO-NBuy$77.50 20.813.10%0.30%
7Abbott LaboratoriesABT-NBuy$96.00 22.213.40%1.90%
8Boston Scientific Corp.BSX-NBuy$38.40 22.413.10%0.00%
9Becton DickinsonBDX-NBuy$50.40 23.411.20%1.50%
10Danaher Corp.DHR-NBuy$64.80 23.610.50%0.60%

Source: Recognia. *Projected this year versus last year

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

Latest Videos

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies